Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.
about
Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trialHIV-1 drug resistance and resistance testing.Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysisHIV-1 antiretroviral resistance: scientific principles and clinical applicationsDrug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy.HIV-1 antiretroviral drug therapy.The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.Efavirenz for HIV-1 infection in adults: an overview.New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.Gender-specific considerations in the antiretroviral management of HIV-infected women.Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitorsVirological failure of staggered and simultaneous treatment interruption in HIV patients who began Efavirenz-based regimens after allergic reactions to nevirapine.Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase.HIV-1 drug resistance mutations: an updated framework for the second decade of HAARTPharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavirCanadian consensus guidelines for the optimal use of etravirine in the treatment of HIV-infected adults.The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug ResistanceEtravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class.Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.Pharmacoeconomics of etravirine.Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.Potential of small-molecule fungal metabolites in antiviral chemotherapy.2014 Update of the drug resistance mutations in HIV-1TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles.TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA).Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.Emerging trends of drug-resistant HIV-1 among drug-treated patients in former blood donors in Hubei, China: a three-year surveillance from 2004 to 2006.
P2860
Q27663609-C4B363DF-2F3C-4D57-81DE-84E1A638B617Q28477586-A1BE9628-7115-47C5-87AA-10E77480FF97Q30245693-4A6AECDC-7DB3-41AE-843C-AF20528F1F4EQ33850152-2C7725AF-1735-4C1C-86CD-781B633B0D94Q33902540-4A35EE84-C58F-4802-A7BF-02946815ECDAQ33988153-8FEA4447-5965-4D26-A04D-51DEBACA836EQ34280466-E9AE04E2-9DE7-4AD2-833C-1941EFD7A913Q34303603-197C5348-0C65-4BEA-A007-D4E44AED0947Q34529310-2171B158-B576-4FB8-B2D8-F7C86B43BCABQ35105844-4C5E70EE-EF8C-4FF4-965F-33EE17CCFB29Q35552675-1F849B0D-8045-42D3-822F-9A9715D07FCBQ35853012-89A712C7-CB54-4DF0-88E8-9E96A895B815Q35917148-579DB9AA-E0A6-4E9F-A24A-E9BF4021F316Q35917519-55970756-6A0F-4518-BAB4-A07DEBAB3323Q35939695-E97A9943-0294-4FAB-A755-0D712F8D7337Q36140662-0536DA35-F602-4C05-BCDA-41499B43C994Q36276790-FEE285CE-2660-48D9-89E3-BBE557489308Q36498272-311CAA8E-AC31-41A6-A98B-3454BF854C57Q36621432-5430A30A-8980-45A6-AC5D-7BB405C06B6CQ36632128-1791F7ED-F604-464F-84D6-0F7BF985E7BAQ36900010-9EE07902-3710-4C26-A2CD-515E38E50847Q36993453-ED8CEBE8-9CFC-43C6-82CC-BB4F92FE59A7Q37032799-35A9C7D7-E926-4EBA-87A0-26FD0A19B15CQ37252113-1928ADC1-AF11-4D0A-9882-E55BE0972F14Q37288671-EAF118F8-5F31-4846-9FFE-CB84857B3C5BQ37621172-382B67E9-937D-4984-BA4B-82596041CC3EQ37649249-5920777C-343A-4C1B-9528-EDE4B4DEFC55Q37800478-CD717821-3877-4629-8B23-8C4193A60702Q37950517-0A980CBC-DFBC-4E8C-BBD1-B3BEFF73907CQ39453829-935C5B0B-1B6F-4E1D-B472-192430DDB327Q39498339-F1575A7B-25DA-4EDE-B219-4B1424C47820Q39771532-9AC65364-A997-4965-A5B3-974D7F229C8BQ40104085-75C9270A-9B27-476C-B5F7-9FBE056835C7Q40410591-8226C865-22A5-4503-A937-0251167F7106Q40425001-7D4C23DD-6DFC-482B-AE1B-D9417EA9B806Q40783234-BCD0BEA1-5008-4BE2-8D78-1703E1FD36B5Q42033549-5DA96F54-ABD7-477A-922E-451158D35080Q42214788-4F1F32B2-05EF-4A24-B3C1-D30BE818E7F8Q42549637-62CB868F-793E-4F2E-9D05-43473063F1E3Q44615578-8C90054A-BB5A-4367-A7BA-58ADE59CE4F0
P2860
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Cross-resistance among nonnucl ...... renz after nevirapine failure.
@en
Cross-resistance among nonnucl ...... renz after nevirapine failure.
@nl
type
label
Cross-resistance among nonnucl ...... renz after nevirapine failure.
@en
Cross-resistance among nonnucl ...... renz after nevirapine failure.
@nl
prefLabel
Cross-resistance among nonnucl ...... renz after nevirapine failure.
@en
Cross-resistance among nonnucl ...... renz after nevirapine failure.
@nl
P2093
P50
P1476
Cross-resistance among nonnucl ...... renz after nevirapine failure.
@en
P2093
Maria G Rizzo
Maria P Trotta
Mauro Zaccarelli
Pasquale Narciso
P304
P356
10.1089/08892220260190308
P50
P577
2002-08-01T00:00:00Z